Published in Arch Pathol Lab Med on September 28, 2016
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol (2005) 6.43
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 3.83
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
The prevalence of pituitary adenomas: a systematic review. Cancer (2004) 2.98
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Hum Pathol (2009) 2.54
Kimura disease: a clinicopathologic study of 21 cases. Am J Surg Pathol (2004) 2.51
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. Am J Pathol (2003) 2.29
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
Interobserver and intraobserver variability in the histological dating of the endometrium in fertile and infertile women. Fertil Steril (2004) 2.22
Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol (2008) 2.21
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. Arch Pathol Lab Med (2013) 2.14
Pitfalls in the biopsy diagnosis of intraoral minor salivary gland neoplasms: diagnostic considerations and recommended approach. Adv Anat Pathol (2014) 2.14
Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol (2014) 2.14
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res (2009) 2.13
Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol (2004) 2.08
Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res (2012) 2.06
The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery (2007) 2.04
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. Arch Pathol Lab Med (2014) 2.02
Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. Cancer (2002) 2.00
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
Prevalence of migraine in patients with a history of self-reported or physician-diagnosed "sinus" headache. Arch Intern Med (2004) 1.84
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Sinonasal-type hemangiopericytoma: a clinicopathologic and immunophenotypic analysis of 104 cases showing perivascular myoid differentiation. Am J Surg Pathol (2003) 1.80
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
Salivary type tumors seen in consultation. Virchows Arch (2009) 1.79
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
Thyroid calcification and its association with thyroid carcinoma. Head Neck (2002) 1.70
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology (2012) 1.68
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. Am J Surg Pathol (2012) 1.58
Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery (2007) 1.57
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res (2008) 1.53
EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer (2011) 1.50
The small abnormal parathyroid gland is increasingly common and heralds operative complexity. World J Surg (2014) 1.50
RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell (2006) 1.47
Primary extracranial meningiomas: an analysis of 146 cases. Head Neck Pathol (2009) 1.47
Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol (2005) 1.47
Positional dyspnea and tracheal compression as indications for goiter resection. Arch Surg (2012) 1.46
Pseudopheochromocytoma of pregnancy. Endocr Pract (2003) 1.45
The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. Cell Metab (2013) 1.45
Sinonasal tumors: a clinicopathologic update of selected tumors. Eur Arch Otorhinolaryngol (2012) 1.43
Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists. Endocr Pathol (2014) 1.43
Parotid gland solitary fibrous tumor: a case report and clinicopathologic review of 22 cases from the literature. Head Neck Pathol (2011) 1.43
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys (2006) 1.42
Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol (2005) 1.41
Papillary synovial metaplasia-like change in oral mucoceles: a rare and previously undescribed histopathologic variant of a common oral lesion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.41
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol (2002) 1.39
"Next-generation" pathology and laboratory medicine. Arch Pathol Lab Med (2011) 1.38
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid (2012) 1.36
Clear cell odontogenic carcinomas show EWSR1 rearrangements: a novel finding and a biological link to salivary clear cell carcinomas. Am J Surg Pathol (2013) 1.36
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 1.36
DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol (2012) 1.34
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab (2009) 1.32
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32